Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference
Isoray (NYSE AMERICAN: ISR), a leader in seed brachytherapy, announced its participation in the American Brachytherapy Society’s annual conference from June 17-19 in Denver, Colorado. The company will host a lunch symposium featuring Dr. Stephen J. Frank from MD Anderson Cancer Center, presenting on MRI-Assisted Radiosurgery (MARS) with Cesium-131. The event aims to enhance precision and reduce toxicity in cancer treatment. Additionally, the Cesium Advisory Group will discuss prostate brachytherapy practices on June 19. Isoray continues to innovate with its Cesium-131 treatment, benefiting patient care.
- None.
- None.
RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Cancer Center at the American Brachytherapy Society’s (ABS) annual conference. The conference is scheduled to take place June 17 – 19 at the Gaylord Rockies Resort in Denver, Colorado.
Isoray’s lunch symposium, Eliminate Uncertainty, Increase Precision & Reduce Toxicity, will be a presentation by Dr. Stephen J. Frank, MD, FABS, MD Anderson Cancer Center, Department of Radiation Oncology. Dr. Frank will present on MRI-Assisted Radiosurgery (MARS), the MD Anderson technique using Cesium-131. The lunch symposium will be held on June 17, 11:30 a.m. – 12:30 p.m., in the Red Rock Room of the Gaylord Rockies Resort.
During the conference a scientific session, Prostate Snap Oral I, will include a presentation on a survey of practices conducted by the Cesium Advisory Group relating to prostate brachytherapy with Cesium-131. This session will be held on Sunday, June 19, 11:30 a.m. – 12:30 p.m., in Colorado Ballroom B of the Gaylord Rockies Resort.
Isoray CEO Lori Woods commented, “It is an honor to have this opportunity to participate in ABS’ prestigious annual conference. As an innovator and leader in state-of-the-art prostate brachytherapy treatment, we remain focused on continuing to provide clinicians with the advanced products and treatment information that allows them to optimize treatment quality and patient care.”
Isoray team members will be available at Booth #16 during the conference to provide the latest updates on Cesium-131.
Isoray is a medical technology company and innovator in seed brachytherapy. Isoray is the world’s only producer of Cesium-131 brachytherapy seeds, commercially known as Cesium Blu. Cesium-131 delivers a minimally invasive and highly targeted treatment to the site of the cancer preserving healthy tissue and organs. Cesium-131’s shorter half-life means the radiation leaves the body faster eliminating other issues for the patient that can come from prolonged radiation exposure. Patients also benefit from the rapid resolution of their side effects allowing them to return to their normal lives quickly.
About Isoray
Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter.
FAQ
What is Isoray's symposium at the 2022 American Brachytherapy Society conference?
When does the American Brachytherapy Society conference take place?
What will be discussed during the Cesium Advisory Group's session at the conference?
Where can attendees find Isoray during the conference?
What is the significance of Cesium-131 in cancer treatment?
